Compare CALM & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALM | CRNX |
|---|---|---|
| Founded | 1957 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 1996 | 2018 |
| Metric | CALM | CRNX |
|---|---|---|
| Price | $79.20 | $55.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $92.00 | $73.70 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 01-07-2026 | 02-26-2026 |
| Dividend Yield | ★ 10.79% | N/A |
| EPS Growth | ★ 84.64 | N/A |
| EPS | ★ 23.74 | N/A |
| Revenue | ★ $4,213,443,000.00 | $1,535,000.00 |
| Revenue This Year | N/A | $505.58 |
| Revenue Next Year | N/A | $879.70 |
| P/E Ratio | $3.26 | ★ N/A |
| Revenue Growth | 36.60 | ★ 47.74 |
| 52 Week Low | $71.92 | $24.10 |
| 52 Week High | $126.40 | $57.99 |
| Indicator | CALM | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 65.93 |
| Support Level | $71.92 | $54.00 |
| Resistance Level | $82.66 | $56.86 |
| Average True Range (ATR) | 2.67 | 3.22 |
| MACD | 0.42 | 0.41 |
| Stochastic Oscillator | 67.69 | 84.85 |
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.